Larvol Delta - INTERIM-RESULTS-FROM-THE-PHASE-I-IBC-0101-STUDY-THE-FIRST-IMMUNE-CHECKPOINT-INHIBITOR-THERAPY-IN-PATIENTS-WITH-EARLY-ALZHEIMER39S-DISEASE

AB-001 - Aubrak Therapeutics

FB3001 - Frontier Biotech

https://info.kenes.com/Flip/ADPD25_ADPD%20-%20Posters/PDF.pdf

Catherine Mummery1; Tommaso Croese2; Dalia Bracha3; Sanjay Keswani2

Mar 11, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev